Scinai Immunotherapeutics Ltd
Company Profile
Business description
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai’s drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
Contact
Hadassah Ein Kerem Campus
2nd Floor, Jerusalem BioPark
Jerusalem
ISRT: +972 89302529
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
31
Stocks News & Analysis
stocks
Earnings Winners: BHP, NAB & TLS lead the pack
stocks
Walmart earnings: Growth in digital buoys margin amid consumer trade-down
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,303.20 | 9.30 | 0.10% |
| CAC 40 | 8,487.65 | 88.87 | 1.06% |
| DAX 40 | 25,184.43 | 140.86 | 0.56% |
| Dow JONES (US) | 49,415.62 | 20.46 | 0.04% |
| FTSE 100 | 10,689.60 | 62.56 | 0.59% |
| HKSE | 26,413.35 | 292.59 | -1.10% |
| NASDAQ | 22,760.96 | 78.23 | 0.34% |
| Nikkei 225 | 56,825.70 | 642.13 | -1.12% |
| NZX 50 Index | 13,308.52 | 135.68 | -1.01% |
| S&P 500 | 6,875.49 | 13.60 | 0.20% |
| S&P/ASX 200 | 9,081.40 | 17.00 | 0.19% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |